Atlas of Genetics and Cytogenetics in Oncology and Haematology

نویسنده

  • Martin Yuille
چکیده

Approximately 1.3% of males and 1% of females in Europe and North America develop leukaemia. CLL is the most common of its subtypes, constituting about 30% of all cases. Its incidence rate increases logarithmically from age 35 and has a median age of onset of 64 years. No single cytogenetic abnormality or gene mutation is found in all CLL cases. However, activation of each of the oncogenes BCL1, BCL2 and BCL3 has been reported in some cases after detection of cytogenetic abnormalities, as has mutation in tumour suppressor genes including those associated with the mutator phenotype and p53 . A putative tumour suppressor locus has been identified on chromosome 13q14. A number of case-control and cohort studies have examined the cancer risks associated with a family history of lymphoproliferative disorders, including CLL (Table 1). These studies showed an elevated risk of lymphoproliferative disorders in relatives. Although no study has systematically examined the incidence of leukaemia by specific subtype in cases and relatives, there is evidence suggesting that the familial risk of leukaemia is greater than the risk of all lymphoproliferative disorders. In the cohort study reported by Goldgar et al using the Utah population database, a 6-fold increase in risk was seen in relatives of patients with lymphocytic leukaemia. This database comprises over 1.4 million records on a population with normal levels of inbreeding that is genetically representative of a Northern European population.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

SERPINB3 (serpin peptidase inhibitor, clade B (ovalbumin), member 3).

Review on SERPINB3, with data on DNA/RNA, on the protein encoded and where the gene is implicated.

متن کامل

Atlas of Genetics and Cytogenetics in Oncology and Haematology, an Interactive Database

The 'Atlas of Genetics and Cytogenetics in Oncology and Haematology' (http://www.infobiogen.fr/services/chromcancer ) is a database devoted to chromosome abnormalities in cancer, cancer-prone diseases and genes involved in cancer. Information presented in each page is concise and updated. This database is made for and by: cytogeneticists, molecular biologists, clinicians in oncology and in haem...

متن کامل

Atlas of Genetics and Cytogenetics in Oncology and Haematology, year 2003

The 'Atlas of Genetics and Cytogenetics in Oncology and Haematology' (http://www.infobiogen.fr/services/chromcancer) contains concise and updated cards on genes involved in cancer, cytogenetics and clinical entities in oncology, and cancer-prone diseases, a portal towards genetics/cancer, and teaching materials in genetics. This database is made for and by researchers and clinicians, who are en...

متن کامل

Atlas of Genetics and Cytogenetics in Oncology and Haematology, updated

The 'Atlas of Genetics and Cytogenetics in Oncology and Haematology' (http://www.infobiogen.fr/services/chromcancer) is an Internet database aimed at genes involved in cancer, cytogenetics and clinical entities in cancer, and cancer-prone diseases. It presents information in concise and updated reviews (cards) or longer texts (deep insights), a (new) case report section, a huge portal towards g...

متن کامل

NMT1 (N-myristoyltransferase 1).

Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N OW8, Canada (PS, SK, RKS); Cancer Research Unit, Saskatchewan Cancer Agency, 20 Campus Drive, Saskatoon, SK S7N 4H4, Canada (PS, SK, RKS); Drug Design and Discovery Research Group, College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5C9, Cana...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2006